Compare Mesoblast Limited (MESO) vs Unilever plc (UL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Unilever plc — how do they compare? Mesoblast Limited trades at $14.33 (market cap $1.75B), while Unilever plc trades at $61.98 (market cap $131.63B). The key difference: Unilever plc is far larger — about 75.2× Mesoblast Limited's market cap, and Unilever plc pays a 3.43% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Unilever plc for 112 Days on average.
| MESO | UL | |
|---|---|---|
Market Cap | $1.75B | $131.63B |
Volume | 239,027 | 2,978,741 |
Sector | Health | Consumer Staples |
52-Week High | $20.96 | $74.59 |
52-Week Low | $13.19 | $55.05 |
Typical Hold Time | 14 Days | 112 Days |
Enterprise Value | $1.83B | $156.65B |
Dividend Yield | — | 3.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Unilever (UL) trades at $61.98, up 1.64% with a bullish technical signal despite recent earnings misses. The company shows strong profitability with 18.32% net margin and 54.56% ROE, though revenue declined to $50.5B in 2025. Analyst sentiment is mixed with 24% buy ratings amid ongoing business restructuring including the planned McCormick food division sale.
UL offers defensive exposure with emerging market growth potential but faces execution risks from portfolio streamlining. The stock presents moderate valuation (P/E 21.59) with cash flow stability, though recent earnings underperformance and regulatory scrutiny on the McCormick deal warrant caution for near-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Unilever plc
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →
